Emmaus Life Sciences, Inc.
EMMA · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,378 | $2,817 | $2,406 | $3,292 |
| % Growth | 19.9% | 17.1% | -26.9% | – |
| Cost of Goods Sold | $247 | $150 | $225 | $309 |
| Gross Profit | $3,131 | $2,667 | $2,181 | $2,983 |
| % Margin | 92.7% | 94.7% | 90.6% | 90.6% |
| R&D Expenses | $50 | $56 | $176 | $137 |
| G&A Expenses | $1,731 | $2,307 | $2,339 | $2,287 |
| SG&A Expenses | $2,386 | $2,981 | $2,985 | $3,403 |
| Sales & Mktg Exp. | $655 | $674 | $646 | $1,116 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,436 | $3,037 | $3,161 | $3,540 |
| Operating Income | $695 | -$370 | -$980 | -$557 |
| % Margin | 20.6% | -13.1% | -40.7% | -16.9% |
| Other Income/Exp. Net | -$2,192 | -$1,355 | -$1,346 | -$1,185 |
| Pre-Tax Income | -$1,497 | -$1,725 | -$2,326 | -$1,742 |
| Tax Expense | $579 | -$590 | $4 | $6 |
| Net Income | -$2,076 | -$1,135 | -$2,330 | -$1,748 |
| % Margin | -61.5% | -40.3% | -96.8% | -53.1% |
| EPS | -0.03 | -0.018 | -0.037 | -0.027 |
| % Growth | -68.5% | 51.2% | -33.2% | – |
| EPS Diluted | -0.03 | -0.018 | -0.037 | -0.027 |
| Weighted Avg Shares Out | 63,866 | 63,866 | 63,866 | 63,866 |
| Weighted Avg Shares Out Dil | 63,866 | 63,866 | 63,866 | 63,866 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $67 | $0 | -$153 |
| Interest Expense | $1,931 | $1,678 | $1,256 | $1,278 |
| Depreciation & Amortization | $15 | $4 | $5 | $5 |
| EBITDA | $449 | -$43 | -$1,065 | -$459 |
| % Margin | 13.3% | -1.5% | -44.3% | -13.9% |